Vivos Therapeutics rises on FDA approval for pediatric sleep apnea device

Vivos Therapeutics

18/09/2024 15:47

** Shares of medtech firm Vivos Therapeutics  VVOS.O  rise
24.4% to five-month high of $3.48 
    ** Co says U.S. FDA has granted clearance for its sleep
apnea device 
    ** The device is designed to reduce nighttime snoring and
treat moderate to severe obstructive sleep apnea in children
aged 6 to 17
    ** Obstructive sleep apnea (OSA) is the most common
sleep-related breathing disorder with symptoms including snoring
and  daytime fatigue
     ** The clearance was based on a study that showed the
device reduced snoring by 58% in pediatric patients and also
reduced other OSA symptoms such as fatigue and lack of attention
    ** There were no safety concerns reported in the study - co 
    ** Including session moves, stock down 71.6% YTD